Jun Gong, MD

In the closing segment of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), moderator and judge Rachna T. Shroff, MD, reflects on how dramatically the treatment landscape has expanded, recalling an era when sorafenib was the only systemic option.

In the second clinical scenario of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), Team Chicago Hot Dog manages a 54-year-old man with NASH-related cirrhosis and BCLC stage C disease, excellent performance status, bulky bilobar disease with a 9.2-cm dominant lesion, Vp3 invasion, two lung metastases, Child-Pugh A5, ALBI grade 1, no varices on recent endoscopy, and a rapidly rising alpha-fetoprotein level.

In the first clinical scenario of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), Team Deep-Dish Pizza manages a 67-year-old woman with hepatitis B cirrhosis and BCLC stage C disease, multifocal bilobar tumors with branch portal vein invasion (Vp3), Child-Pugh A6, ALBI grade 2, and an elevated alpha-fetoprotein level.

In the third debate round of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), moderator Rachna T. Shroff, MD, presents a Child-Pugh A, BCLC stage B patient eligible for locoregional therapy, asking whether clinicians should prioritize locoregional treatment or introduce systemic therapy earlier.

In the second debate round of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), moderator Rachna T. Shroff, MD, presents a treatment-naive patient with Child-Pugh B7, BCLC stage C disease and compromised liver function, asking how limited liver reserve should influence frontline selection.

In the first debate round of this Cancer Network Face Off on advanced hepatocellular carcinoma (HCC), moderator Rachna T. Shroff, MD, presents a patient with Child-Pugh A, BCLC stage C disease and bulky tumor burden, asking each team to defend a frontline regimen.

The panel discusses the timing of systemic therapy alongside locoregional treatment in intermediate-stage hepatocellular carcinoma (HCC), focusing on the EMERALD-1 results.

Jun Gong, MD, presents the EMERALD-1 trial for Team Chicago Hot Dog, reviewing the phase 3, randomized, double-blind study of transarterial chemoembolization (TACE) with durvalumab, with or without bevacizumab, in unresectable hepatocellular carcinoma (HCC) amenable to embolization.

The panel discusses whether the SIERRA safety data support using the STRIDE regimen, tremelimumab plus durvalumab, in patients typically excluded from frontline hepatocellular carcinoma (HCC) trials.

James J. Harding, MD, presents the SIERRA study for Team Deep-Dish Pizza, reviewing the phase 3b, single-arm trial of the STRIDE regimen, tremelimumab plus durvalumab, in first-line unresectable hepatocellular carcinoma (HCC) with poor-prognosis features.

The panel discusses ipilimumab dosing and the management of immune-related toxicity with nivolumab plus ipilimumab in advanced hepatocellular carcinoma (HCC).

Ronan W. Hsieh, MD, presents the CheckMate 9DW trial for Team Chicago Hot Dog, reviewing the phase 3 study of nivolumab plus ipilimumab versus investigator's choice of lenvatinib or sorafenib in first-line unresectable hepatocellular carcinoma (HCC).

The panel discusses how to apply real-world evidence to frontline regimen selection in advanced hepatocellular carcinoma (HCC).

Midhun Malla, MD, presents real-world data for Team Deep-Dish Pizza, reviewing a multicenter retrospective study comparing frontline atezolizumab plus bevacizumab with durvalumab-based therapy in advanced hepatocellular carcinoma (HCC).

This segment focuses on assessing bleeding and variceal risk before initiating anti-VEGF therapy with atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC).

The panel discusses long-term survival and quality of life with atezolizumab plus bevacizumab in advanced hepatocellular carcinoma (HCC).

Reviewing the HIMALAYA Trial of Tremelimumab Plus Durvalumab in Unresectable HCC

Navigating the Treatment Landscape in Advanced Hepatocellular Carcinoma

Reviewing the IMbrave150 Trial of Atezolizumab Plus Bevacizumab in Unresectable HCC

Examining ALBI Grade and Portal Vein Thrombosis in Frontline HCC Treatment

Jun Gong, MD, and Daneng Li, MD, spoke about trials they feel can impact the gastrointestinal space during a CancerNetwork® X Space.

Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

Jun Gong, MD, gives his perspective on neoadjuvant chemotherapy in elderly patients with muscle-invasive bladder cancer.

The conversation with Jun Gong, MD, focused on the evolving relationship between oncologists who treat prostate cancer and genetic counselors.

Jun Gong, MD, gives his perspective on a review article published in ONCOLOGY about the necessary relationship between medical oncologists and genetic counselors to help treat patients with prostate cancer.

On this week’s podcast, Jun Gong, MD, spoke with CancerNetwork® about the potential role of plasma glutamine as a biomarker for patients with localized prostate cancer.

This study investigated the biomarker potential of glutamine among known prognostic variables in localized prostate cancer.

Experts in the field review integration of approved PARP inhibitors into advanced prostate cancer clinical practice.